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The management of incidental pancreatic cystic lesion (PCL) can be challenging. With a better understanding of the natural course of PCL, we recommend
surveillance of PCL without high-risk stigmata for at least 5 years. The importance of interventional endoscopic ultrasound (EUS) in establishing a speciﬁc
diagnosis and treatment cannot be over-emphasized. This review aims to give an overview on the latest developments in EUS-guided ﬁne needle
aspiration and EUS-guided pancreatic cyst ablation.
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Incidental pancreatic cysts are diagnosed with increasing fre-
quency because of widespread utilization of cross-sectional imag-
ing. With advances in imaging techniques, asymptomatic
(incidental) pancreatic cystic lesions (PCL) can be detected with
increased sensitivity. Two consecutive retrospective case series
from the same tertiary surgical centers reﬂect this trend.1,2 The
initial case series reviewed 212 patients who were diagnosed with
PCL (mean size ¼ 33 mm) from 1997 to 2002, with 36% of them
being incidentally detected. From 2004 to 2007, 401 patients were
detected with PCL (mean size ¼ 27 mm), with 71% of them
asymptomatic.Epidemiology and natural course
In the general population, the prevalence of pancreatic cyst is
estimated to be 2.6%.3 In the previous retrospective study, contrast-
enhanced multidetector computed tomography (CT) scans of the
abdomen were reviewed from 2832 consecutive examinations to
identify pancreatic cysts. Patients with a history of pancreatic le-
sions, with predisposing factors for pancreatic disease, or whowere
referred for CT of the pancreas were excluded. Mean cyst size on
detection was 8.9 mm (range 2–38 mm), and 85% of the cysts were
solitary. Cyst occurrence was strongly correlated with increasing
age and Asian ethnicity. Approximately 10% of patients older than
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With increasing data from clinical studies, we have a better
understanding of the natural history of PCL. In an earlier retro-
spective cohort study, 112 patients who had PCL but who were not
indicated for surgery were followed-up to assess malignant pro-
gression, growth of cysts, need for surgery, and mortality.4 Exclu-
sion criteria were evidence of pancreatitis or a history of von
Hippel–Lindau disease, polycystic disease of the kidney or liver, or
cystic ﬁbrosis. During follow-up for the median period of 72.3
months, the size of the PCL increased in 18 patients (16.1%). Six of
these patients experienced growth of their PCL after 5 years of
follow-up. Twenty-six patients underwent surgery during follow-
up, and four malignant cysts were detected. The overall rate of
malignant progression during follow-up was 3.6%. The presence of
mural nodules or solid components was independently associated
with the presence of malignant PCL. The authors concluded that
most PCL show favorable prognosis, but long-term surveillance for
> 5 years was recommended. In another study, Lee et al investi-
gated natural history of PCL with 182 patients who have incidental
PCL. The mean follow-up period was 35.4 months. The results of
this study showed that cyst size increased in 54 patients, did not
change in 107, and decreased in 21 during follow-up period, and
three cases were found to have developed a malignancy. The au-
thors also recommended long-term regular follow-ups of PCL.5
A clear understanding of the long-term natural behavior of PCL
is essential for investigators to establish a follow-up plan and toHong Kong
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data is needed.
Diagnosis and investigations
Documentation of demographic data and detailed history taking
are the ﬁrst important steps for diagnosis. If the patient is male,
mucinous cystic neoplasm (MCN) is less likely because it mainly
occurs in women. If the patient is young and female, solid pseu-
dopapillary neoplasm should be suspected. MCN tends to occur in
middle-aged patients, serous cystadenoma (SCA) can occur in
middle-aged to elderly people, and intraductal papillary mucinous
neoplasm (IPMN) mostly occurs in the elderly. Pseudocysts are
unlikely if there is no history of pancreatitis or trauma. Neuroen-
docrine tumor and SCA should be considered if there is a history of
multiple endocrine neoplasia or von Hippel-Lindau syndrome.
Invasive carcinoma is uncommon in patients with an asymp-
tomatic cyst of 1 cm.6 Thus, follow-upwithout further investigation
is generally acceptable.
For cysts > 1 cm or for symptomatic cysts, further evaluation
with gadolinium-enhanced magnetic resonance imaging (MRI)
plus MR cholangiopancreatography or pancreatic protocol multi-
detector CT is recommended. MRI is the imaging procedure of
choice for evaluating a pancreatic cyst due to its better visualization
of pancreatic ductal communication (sensitivity 91–100%, speci-
ﬁcity 90%), cyst septation, and solid component.7
CT and MRI are valuable tools to detect pancreatic cysts. How-
ever, the accuracy of MRI and CT to make a speciﬁc diagnosis is
suboptimal, with reports of 39–50% and 40–44% respectively.8,9 In
predicting benign or malignant disease, CT has a sensitivity and
speciﬁcity of 36–71% and 64–100%, respectively, whereas MRI has a
sensitivity and speciﬁcity of 65–77% and 58–89%, respectively.
Studies on 18-ﬂuorodeoxyglucose positron emission tomogra-
phy (PET) scan studies have produced varying results. Three studies
investigated the ability of PET-CT to differentiate between benign
and malignant lesions.10–12 Deﬁnitive histology was available in all
patients. The reported sensitivity and speciﬁcity ranged from 57–
94% and 65–97%, respectively. A recent study comparing PET-CT
with CT to predict malignancy showed a sensitivity and speci-
ﬁcity of 100% and 87% respectively.13 Further evaluation of PET-CT
in multicenter controlled trials is warranted.
Role of endoscopic ultrasonography in diagnosis and risk
stratiﬁcation
Endoscopic ultrasonography (EUS) has become an important
tool in the diagnosis and risk stratiﬁcation of pancreatic cysts. It can
accurately visualize the cyst morphology, assess vascular pattern by
contrast harmonic scan, and perform ﬁne-needle aspiration (FNA)
for evaluation of cytology and molecular markers.Morphology
Many PCL have typical features. In order to make a presumptive
diagnosis by EUS examination, cyst size, number, and shape, state
of cyst wall, internal cyst features, presence of calciﬁcation or
scarring, communication with pancreatic duct, presence of mural
nodules, and lymphadenopathy should be carefully inspected
(Fig.1 and 2). However, a number of studies showed lowaccuracy of
EUS alone to determine benign versus malignant disease.14 In
addition, interobserver agreement among endosonographers to
morphologically differentiate between mucinous and non-
mucinous cysts was shown to be only fair (k ¼ 0.24).15 Thus, EUS
alone does not appear to be very reliable to establish a speciﬁcdiagnosis or to differentiate between benign andmalignant disease
(Table 1).16EUS-FNA with cyst ﬂuid cytology
Cystic ﬂuid aspirate is acellular or with minimal cellularity in up
to 72% of aspirated cysts.17 Analysis of cystic ﬂuid aspirate can be
used to differentiate mucinous from nonmucinous cysts with a
sensitivity, speciﬁcity, and accuracy of 12.5–27%, 90–100%, and 55%,
respectively.18,19 In another report, cytology was shown to have an
accuracy of 50% in differentiating benign frommalignant disease.20
Aspiration may be difﬁcult in SCA because of its microcystic
structure. However, the presence of glycogen-rich cells is highly
speciﬁc to SCA.21Cystic ﬂuid analysis and molecular markers
Carcinoembryonic antigen (CEA) in cyst ﬂuid is one of the most
studied tumor markers. It is a useful marker to predict the presence
of mucinous cysts but not of malignancy.21 However, the reported
cut-off values vary. In a large prospective study in 2004, the utility
of CEA, CA19-9, CA72-4, CA15-3, and CA125 to differentiate
mucinous and nonmucinous cysts was evaluated in 341 patients
who underwent EUS-FNA of pancreatic cysts.22 That study sug-
gested that an intracystic CEA level of  192 ng/mL could predict
the presence of mucinous cysts with a diagnostic accuracy of 79%,
which was superior to either EUS morphology alone (51%) or
cytology (59%). However, with this cut-off, about one-ﬁfth of the
cases with genuine mucinous cysts would be missed as false neg-
atives. Another study performed a pooled analysis of 12 trials and
demonstrated that when CEA levels were  800 ng/mL, the spec-
iﬁcity for differentiating mucinous cysts was 98%, whereas the
sensitivity dropped to 48%.23 By contrast, a CEA level 6 ng/mL has
been shown to be highly speciﬁc for serous/non-mucinous cysts.
Hence, we can only conclusively determine the nature of the cysts
when the intracystic ﬂuid CEA is  6 ng/mL or  800 ng/mL.
As an enzymatic marker, cyst ﬂuid amylase is useful in the dif-
ferentiation of pseudocysts from cystic neoplasm. An amylase level
< 250 U/L essentially excludes pseudocysts. Another enzymatic
marker, serine peptidase inhibitor Kazal type 1 (SPINK1), is a
polypeptide synthesized by several types of tumors and cell lines.24
A previous study evaluated cyst ﬂuid SPINK1 levels in resected
pancreatic cystic lesions and found that the levels were signiﬁ-
cantly higher in main-duct/mixed type IPMN and MCN patients,
than in SCN and branch-duct (BD) IPMN patients.25 Furthermore,
SPINK1 may be a predictive marker of the need for surgery in PCL.
Identiﬁcation of genetic mutations may represent the next
frontier for research. The oncogene GNAS was recently detected in
IPMN tissue as well as in duodenal juice.26 Some reports have
suggested that GNASmutations are prevalent in IPMN, especially in
the intestinal form and in invasive IPMN.27 K-ras, p16, and p53
mutations have also been reported to be associated with progres-
sion of pancreatic cysts from nondysplastic to dysplastic cysts.28
Treatment strategy
Surgery
Surgery remains the mainstay treatment for pancreatic cystic
neoplasms, either to relieve symptoms in nonmucinous benign
disease, or to prevent or eliminate malignant neoplasms.
Early resection of premalignant lesions is associated with sur-
vival beneﬁt. For example, the prognosis of a resected benign IPMN
is excellent with a 10-year survival rate of > 95% or both main-duct
Fig. 1. Branch-duct intraductal papillary mucinous neoplasm. (A, B) computed tomography showing a pancreatic cystic neoplasm at the head of the pancreas and pancreas body
respectively. (C) Endoscopic ultrasound at the head of the pancreas showing a 3 cm septated cyst in communication with the pancreatic duct. The main pancreatic duct is mildly
dilated, measuring up to 5 mm. (D) Endoscopic ultrasound at the pancreatic body showing a 2.7 cm multiseptated cyst.
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lower when invasive IPMN-carcinoma is resected.30
The 2012 international consensus guidelines outline the man-
agement recommendations speciﬁcally for IPMN and MCN.31
“Worrisome features” refer to main pancreatic duct (MPD) dilata-
tion of 5–9 mm, cyst size > 3 cm without “high-risk stigmata”,
presence of a nonenhanced mural nodule, thickened nonenhanced
cyst wall, and abrupt changes in MPD caliber with distal pancreatic
atrophy. “High-risk stigmata” describes a cyst with MPD dilatation
> 10 mm, or the presence of an enhanced mural nodule.
Surgery is recommended in patients with cystic lesions in as-
sociation with obstructive jaundice, all surgically ﬁt patients with
main-duct-IPMN or MCN, and BD-IPMN patients with high-risk
stigmata such as an enhanced solid component. Surgical manage-
ment of BD-IPMN without high-risk stigmata is subjected to
ongoing controversy with regard to the timing and extent ofFig. 2. Serous cystic neoplasm. Endoscopic ultrasound showing typical central stellate
calciﬁcation and a microcystic component.resection, mainly because a highly reliable marker of malignant
transformation is lacking. Currently, BD-IPMN without high-risk
stigmata is usually monitored closely without immediate surgery.
SCN is rarely associated with malignancy. Surgery is not indi-
cated unless SCN causes mechanical complications due to a large
size (usually> 4 cm), or it shows a signiﬁcant growth tendency of>
2–10 mm/year.32,33 Solid pseudopapillary neoplasm is associated
with some risk of malignancy, whereas malignant transformation
of neuroendocrine tumor is difﬁcult to predict. Surgery is best
decided in a case-by-case manner.
Limitation of surgery
Pancreatic resection including pancreatoduodenectomy and
pylorus-preserving pancreatoduodenectomy is traditionally a
major operation with signiﬁcant risk. Even in high-volume centers,
pancreatectomy is associated with a mortality rate of 0.5–2%, and a
morbidity rate of 20–40%. In 20% of cases, the preoperative diag-
nosis is premalignant or malignant, but the lesion is found to be
pathologically benign.
EUS-guided pancreatic cyst ablation
In some cases, achieving patient satisfaction is difﬁcult when
discussing options of conservative or surgical management for
mucinous PCL without an eminent risk of malignancy. Patients are
often not satisﬁed with either choice: the former involving no
treatment of a precancerous disease and the latter being associated
with signiﬁcant complications. Therefore, EUS-guided pancreatic
cyst ablation presents an attractive and practical alternative.
EUS-guided ethanol lavage  paclitaxel injection
EUS-guided ethanol lavage plus paclitaxel injection is a prom-
ising therapeutic modality currently being developed. A pilot study
in 2005 showed that ethanol lavage is safe and effective in
Table 1 Summary of Endoscopic Ultrasound Alone in the Diagnosis and Risk Stratiﬁcation of Pancreatic Cystic Lesions
Author No. of patients Sens. (%) Spec. (%) PPV (%) NPV (%) Accuracy (%)
Diagnosis Koito et al 199745 52 92–96
Need for surgery Frossard et al 200346 127 71 30 49 40
Determining malignancy Sedlack et al 200219 34 91 60 82
Gerke et al 20066 66 48–87 49–80 65–67
Kim et al 201147 51 96 71.4
Lim et al 201348 298 84.2 33.3
Note. From “Imaging of indeterminate pancreatic cystic lesions: a systematic review,” by M.J. Jones, A.S. Buchanan, C.P. Neal, A.R. Dennison, M.S. Metcalfe, and G. Garcea, 2013,
Pancreatology, 13, pp. 436–42. Copyright 2013, IAP and EPC. Adapted with permission.
NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, speciﬁcity.
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cyst epithelium by rapid protein precipitation, cell membrane lysis,
and vascular occlusion. Treatment response is further augmented
by adding a chemotherapeutic agent, most commonly paclitaxel,
which acts by inhibiting the disassembly of microtubules during
cell division and subsequently inducing apoptosis.
In selected cases, with a curvilinear echoendoscope, the target
cyst can be punctured via the transgastric or transduodenal route
with a 22-gauge FNA needle. After aspiration of the cyst ﬂuid,
ethanol is injected at a volume equal to that initially aspirated. To be
effective, ethanol should be at a concentration of 40% or higher,
with 99% ethanol most commonly administered. Ethanol is left for
20–40 minutes followed by evacuation. Paclitaxel can then be
injected and left in the cyst cavity. Paclitaxel is prepared as an oil-
based viscous form, which minimizes the risk of leaking out of the
cyst. Plasma paclitaxel concentrations after EUS-guided pancreatic
cyst ablation are almost undetectable and rarely cause systemic
side effects. Cross-sectional imaging is usually performed 3–4
months after the injection to evaluate the resolution or change in
cyst size (Fig. 3).Fig. 3. Complete remission of mucinous cystic neoplasm after endoscopic ultrasound guided
of the pancreas. (B) Endoscopic ultrasound revealing a uniloculated cyst without communic
Ablation was performed with ethanol lavage followed by paclitaxel injection. (C) Follow-up
(1.2 cm) with peripheral calciﬁcation. (D) Follow-up computed tomography 3 years later sho
are not evident.Cyst ablation with ethanol plus paclitaxel is usually well toler-
ated. Abdominal pain is the most common acute complication and
is reported in up to 20% of cases within the ﬁrst week. Other
complications include acute pancreatitis (2–4%), intracystic hem-
orrhage (2%), fever, transient hypotension, alcoholic intoxication,
and rarely splenic or portal venous thrombosis. To date, no
procedure-related death has been reported.
Another potential disadvantage of this technique is that it
commonly induces perilesional ﬁbrosis, which may make future
pancreatic surgery more difﬁcult.Proposed indication
Cyst ablation may be considered for the following conditions35:
(1) a 2–5 cm benign uni/oligo-loculated MCN or BD-IPMN (without
high-risk stigmata) located in the head or body of the pancreas; (2)
2–5 cm benign uni/oligo-loculated MCN or BD-IPMN (without
high-risk stigmata) located in the tail of the pancreas in a patient
otherwise unﬁt for surgery (3) MCN or IPMN with high-risk stig-
mata in a patient who refuses surgery, or who does not tolerateablation. (A) Computed tomography showing a solitary 3.6 cm cystic lesion at the body
ation to the pancreatic duct. Clinically, it is consistent with mucinous cystic neoplasm.
computed tomography 1 year later showing markedly shrinkage of the cystic lesion
wing further reduction in the size of the residual cyst, measuring < 1 cm. New lesions
Table 2 Summary of Reports on Endoscopic Ultrasound -guided Pancreatic Cyst Ablation
Author No. of patients Ablative Agent Follow-up period, mo Complete resolution, % Epithelial denuded in resected cyst, %
Gan et al 200534 25 5–80% ethanol 6–12 35% (8/23) Variable, up to 100% (n ¼ 5)
DeWitt et al 200937 42 80% ethanol 3–4 after 2nd lavage 33% (12/36) 50–100% (n ¼ 3)
DiMaio et al 201136 13 80% ethanol 13 after 1st lavage 38% (5/13) N/A
Oh et al 200838 14 80/99% ethanol þ paclitaxel Median 9 (6–23) 79% (11/14) N/A
Oh et al 201439 10 99% ethanol þ paclitaxel Median 8.5 (6–18) 60% (6/10) Partial (n ¼ 2)
Oh et al 201140 47 99% ethanol þ paclitaxel Median 20 (12–44) 62% (29/47) 0–100% (n ¼ 4)
N/A, not available.
Gastrointestinal Intervention 2014 3(1), 40–4544surgery; and (4) macrocystic benign SCN with tendency to develop
mechanical complications.
The decision to proceed to cyst ablation relies on a precise
diagnosis. In daily practice, around 50% of incidental PCL are clas-
siﬁed as indeterminate cysts after thorough initial imaging and
EUS  FNA. The majority of these indeterminate cysts are thought
to belong to BD-IPMN or MCN. Nevertheless, further research is
needed to address accurate diagnosis, surveillance, and treatment
in this group of lesions.
Results and outcomes
From 2005 to 2012, six published prospective studies evaluated
the role of EUS-guided pancreatic cyst ablation.34,36–40 There is
heterogeneity among these studies in terms of different ethanol
concentrations used, different modalities to deﬁne outcome
(radiologic vs. EUS), and different design for serial lavage (booster).
Three studies used ethanol alone34,36,37 and three added paclitaxel
with ethanol.38–40 The reports for EUS-guided pancreatic cyst
ablation are listed in Table 2.
Cyst resolution or size reduction can be regarded as a surrogate
for elimination of cyst epithelium. In the three studies that used
ethanol alone for ablation, complete cyst resolutionwas achieved in
33–40% of patients.34,36,37 Two of these studies evaluated the his-
tology of surgically resected cysts and showed various degrees (up
to 100%) of cyst epithelial denudation.36,37
Oh and colleagues38 reported that the addition of paclitaxel
signiﬁcantly increases CT-deﬁned cyst resolution (size < 5% of the
original cyst volume) by 60–79%. The degree of epithelial denu-
dation ranged from 0% to 100% in resected specimens.
Response to cyst ablation can be inﬂuenced by cyst character-
istics, ablative agents used, and the number of ablations. For cyst
factor, a size of the cyst < 3.5 cm was shown to predict complete
resolution. Thick cyst wall, multiple septations, and presence of
mural nodules are associated with a poor response. Addition of
paclitaxel consistently achieved a higher rate of cyst resolution. In
addition, treatment with two sessions appears to increase the
resolution rate compared with one ethanol ablation.
EUS-guided radiofrequency ablation or photodynamic ablation
Radiofrequency ablation (RFA) is widely used in oncology. This
method works by emitting heat energy to induce coagulative ne-
crosis in the target tissue.41 Recently, there has been growing in-
terest in EUS-guided RFA because pancreatic tissue is very
thermosensitive, and EUS has the advantage of real-time visuali-
zation and easy access to the pancreas.
Currently, EUS-guided RFA is under investigation for its potential
clinical applications. EUS-compatible pilot RFA needles allow for the
transduodenal application of RFA. This needle is an 18-gauge endo-
scopic RFA electrode composed of an electrode covered by protective
tubing, an electrode handle, and catheters for the cooling system.
The degree of tissue destruction is proportional to the RF energy
used, duration of ablation, and length of the RF probe. According tosmall animal studies, RFA at the pancreatic body and tail appears to
be safe with minimal complications, whereas RFA at the pancreatic
head is associated with pancreatitis in 20% of cases.42,43
EUS-guided photodynamic therapy with the photosensitizing
agent porﬁmer sodium has been shown to be effective in ablation of
pancreatic tissue. An animal study demonstrated localized tissue
necrosis within the pancreatic tail (range 6.6 – 30.5 mm in diam-
eter). The diameter of the necrotic tissue was directly related to the
dose of light. No post-procedural complications were observed.44
EUS-RFA or EUS-photodynamic therapy may have some poten-
tial but are currently in the preliminary stage of development. The
efﬁcacy and safety proﬁle of these techniques require conﬁrmation
in large studies with longer follow-up periods. Histological quan-
tiﬁcation of cyst epithelial or cancer tissue elimination is desirable
in future research.
Conclusion
Asymptomatic and incidentally found pancreatic cysts are
observed more frequently. Such lesions generally have indolent
behavior with a low rate of malignant transformation. Surveillance
of selected cases for at least 5 years should be considered. EUS and
FNA cytology and molecular marker assessment are important to
establish a speciﬁc diagnosis and to differentiate benign from
premalignant/malignant lesions.
EUS-guided pancreatic cyst ablationwith ethanol  paclitaxel is
safe and effective. It is a practical alternative treatment in selected
patients who are not candidates for or who refuse surgery.
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